ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / KOD / dividends
IMVT (37) CGON (42) SRRK (41) CRSP (35) ⌘ Pro Terminal β†’

Kodiak Sciences Inc (KOD) Dividend Safety Gauge & 10-Year DRIP Compounder

$97.63 -1.57% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $97.17

Kodiak Sciences Inc (KOD) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ β€’ SELL / AVOID Cap $6.14B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KOD Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is KOD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Kodiak Sciences Inc (NASDAQ: KOD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $97.63 (-1.57% 1D, market cap $6.14B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, KOD ranks #211 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does KOD compare to IMVT and CGON in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), KOD carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, IMVT (Immunovant Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $5.87B) and CGON (CG Oncology Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -20.8%, cap $5.49B). Among the 5-stock peer group, KOD leads on earnings multiple (N/A) while CGON leads on capital efficiency (-20.8% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KOD?
β–Ό

Per KOD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001468748), Kodiak Sciences Inc generated $656.3M in revenue (+25.4% YoY), -$230.0M in net income, and -$136.5M in free cash flow against $351.5M in total assets and $87.4M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $97.17 (-0.47%)🧬 Dilution Drag (+1.92% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY β€’ 51.0% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D+
025507510054
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D Β· Rk C-
Cash (8)Whales (17)SEC (14)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-1.8% Base Target
$113 Bull$96 Base$75 Bear
πŸ“¬ FREE KOD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for KOD)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (54/100 Composite)
πŸ” WHY KOD SCORES 54/100 (D+) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+17/20 pts (31% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (26% of score)

Altman Z-Score 16.70 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 4/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
46
Grade D$88.12-2.7% Next Q
Q2 (-2Q)
49
Grade D$85.78+17% Next Q
Q3 (-1Q)
51
Grade C-$100.40-2.8% Next Q
Current
54
Grade D+$97.63-0.7% Hist 90D Ξ±
Trajectory: D (46) β†’ D+ (54)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a KOD Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While KOD currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($68.59) and Max Pain ($102.51) forces dealer call-delta covering toward $113.13.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KODβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œKOD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 54%NO 46%Trade / Inspect Odds β†’
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $17,081

Est. Year-10 Shareholder Yield: $102/yr
$10.6K
Yr 1
$11.1K
Yr 2
$11.7K
Yr 3
$12.4K
Yr 4
$13.1K
Yr 5
$13.8K
Yr 6
$14.5K
Yr 7
$15.3K
Yr 8
$16.2K
Yr 9
$17.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KOD)

  • βœ“Walkthrough of KOD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
KOD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +128.86%β–² ASCENDING TRIANGLE
2026-11-04O $99.18H $99.18L $97.63C $97.63VOL 595.7K
SUP: $30.05SMA50: $68.59SMA200: $43.54
$109.7$85.98$62.23$38.48$14.73SUP $30.05$97.632026-05-052026-06-222026-08-062026-09-222026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KOD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ KOD Butterfly Map β†’ + Track KOD β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
27.0%/yr Implied 5Y Growth

vs. +25.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KOD today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for KOD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KOD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KOD)

Health Care Rank #211 of 1015 βš”οΈ IMVT vs KOD Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (KOD vs. IMVT, CGON, SRRK, CRSP)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Kodiak Sciences Inc (KOD) ranks #211 by composite RQD confidence (54/100, grade D+) and #141 by equity capitalization ($6.14B). Within this direct 5-issuer industry benchmark cohort, KOD leads on earnings valuation at N/A trailing P/E, while CGON leads on capital efficiency and profitability with -20.8% ROIC and β€” gross margin. KOD currently leads its immediate peer cohort in composite quantitative strength at 54/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KOD ACTIVE
Kodiak Sciences Inc
D+ 54/100 β€” β€” -35.0% -1.57% $6.14B Benchmark Subject
IMVT
Immunovant Inc.
D- 37/100 β€” β€” -35.0% -2.60% $5.87B /imvt-vs-kod β†’
CGON
CG Oncology Inc.
D- 42/100 β€” β€” -20.8% -4.20% $5.49B /cgon-vs-kod β†’
SRRK
Scholar Rock Holding Corporation
D- 41/100 β€” β€” -35.0% -2.25% $5.23B /srrk-vs-kod β†’
CRSP
CRISPR Therapeutics AG
D- 35/100 β€” β€” -30.6% -2.78% $4.83B /crsp-vs-kod β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001468748 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kodiak Sciences Inc (KOD) reported GAAP revenue of $656.3M (+25.4% vs. FY2024 revenue of $523.2M , and -15.5% cumulative change since FY2023) , GAAP net income of -$230.0M, operating cash flow of -$136.0M, and free cash flow of -$136.5M (-16.0% YoY). On the balance sheet, KOD closed FY2025 with $351.5M in total assets against $87.4M in total debt (Altman Z-Score: 16.70, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $656.3M -$230.0M -$136.0M -$136.5M $351.5M $87.4M
FY2024 (FY) 2024-12-31 $523.2M -$176.2M -$117.3M -$117.7M $335.6M $83.4M
FY2023 (FY) 2023-12-31 $776.5M -$260.5M -$154.2M -$154.2M $3.47B $812.1M

3. KOD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KOD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Kodiak Sciences Inc (NASDAQ: KOD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $97.63 (-1.57% 1D, market cap $6.14B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, KOD ranks #211 in composite RQD confidence.

How does KOD compare to IMVT and CGON in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), KOD carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, IMVT (Immunovant Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $5.87B) and CGON (CG Oncology Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -20.8%, cap $5.49B). Among the 5-stock peer group, KOD leads on earnings multiple (N/A) while CGON leads on capital efficiency (-20.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KOD?

Per KOD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001468748), Kodiak Sciences Inc generated $656.3M in revenue (+25.4% YoY), -$230.0M in net income, and -$136.5M in free cash flow against $351.5M in total assets and $87.4M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KOD trading relative to its 50-day, 200-day, and 52-week technical levels?

KOD last traded at $97.63 (-1.57% on volume of 595,652 shares), positioning the stock +42.34% above its 50-day simple moving average ($68.59) and +124.23% above its 200-day simple moving average ($43.54). Across its 52-week range of $15.83 to $104.00, KOD sits at the 92.8% percentile with a 14-day RSI of 63.0 (BULLISH MOMENTUM) and an implied next-earnings move of Β±12.5% ($85.43 to $109.83).

Direct Sub-Reports: KOD RQD Cockpit KOD 12M Forecast KOD Earnings & Move KOD Dividends & DRIP KOD Insiders & 13F KOD Whale Options KOD Profit Sankey KOD News & Why
ROARABLE RATING BRIEF β€’ RQD 54/100 (D+) βœ“ SEC XBRL & RQD VERIFIED

KOD β€” Kodiak Sciences Inc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Kodiak Sciences Inc (KOD) earns a live Roarable RQD composite score of 54/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $97.63 (-1.57% 1D, market capitalization $6.14B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of -13.3%, and free cash flow yield of -2.16%.
  • Whale 13F & Options Flow (17/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (14/20): Incorporates a 0.90x equity beta, Altman Z-Score of 16.70, Piotroski F-Score of 4/9, and Debt/Equity of 0.52x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Kodiak Sciences Inc is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The issuer has a market capitalization of $6.3B. The reported revenue of β€” across all three periods indicates no recognized revenue in the source financials.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Kodiak Sciences Inc (KOD) reported $656.3M in annual revenue (up from $523.2M in FY2024, +25.4% YoY) and -$230.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($776.5M revenue, -$260.5M net income) through FY2025, KOD scaled operating cash flow to -$136.0M and free cash flow to -$136.5M, backed by $351.5M in total assets against $87.4M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D+ β€’ RQD 54/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -2.16% and institutional whale pillar of 17/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $15.83 – $104.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -13.3% operating margins and a 0.90x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply chain is NONE, with no upstream or downstream links and no proprietary signals recorded. Upstream suppliers, downstream customers, and sector correlations are therefore β€” The clinical-trial readout flagged on the news wire is the primary 2nd-order item to monitor, since outcomes in the company's pipeline would affect the balance-sheet trajectory given that the company currently reports no revenue and negative free cash flow in every period shown.

  • Key Question #1: Can KOD sustain or expand its -13.3% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $656.3M and free cash flow of -$136.5M, how will capital allocation balance growth reinvestment against $87.4M in total debt?
  • Key Question #3: How sensitive is KOD's 35.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.90x)?

KOD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kodiak Sciences Inc (KOD) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to KOD Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KOD Bull vs. Bear Conversation Board β€” What's Your Call at $97.63?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KOD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KOD:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER β€’ Options Flow Specialist πŸ‚ BULLISH 🎯 Target: $119.02 (+20.0%)
πŸ“Œ Pinned Debate

Institutional positioning scores 18 of 20 on the Whale 13F Flow pillar, the strongest pillar in the RQD rating, and cash grew to $209.9

Long KOD at $99.18 targeting $119.02. Institutional positioning scores 18 of 20 on the Whale 13F Flow pillar, the strongest pillar in the RQD rating, and cash grew to $209.9M in FY 2025.. Institutional whale score is 17/20 and the risk/reward vs. the $18.05 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader πŸ‚ BULL

Both sides have a point here β€” KOD's 14/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

ME MeanReversion_88 RQD DEBATE OPENER β€’ Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $80.34 (-19.0%)
Spot @ $99.18

ROIC of -35%, FCF yield of -2.16%, and zero reported revenue across all three periods leave the fundamental cash engine scoring 8 of 20

Sitting on the sidelines or leaning short KOD above $99.18. ROIC of -35%, FCF yield of -2.16%, and zero reported revenue across all three periods leave the fundamental cash engine scoring 8 of 20.. Until Fundamental Cash Engine (8/20) and FCF yield (-2.16%) inflect higher, upside is capped near $104.00.

LIVE TAPE